Hima Makala

This study shows that reducing GPC3 in liver cancer cells increases their sensitivity to radiation by extending G2/M arrest and activating the ATM/CHK2 pathway, with clinical evidence linking high GPC3 to worse outcomes in radiotherapy-treated HCC patients.

A multimodal pipeline defines and validates tumor-selective surface targets for radiotheranostic use in hepatocellular carcinoma.

A β-galactose-cleavable linker reduces kidney toxicity, enhances tumor targeting and therapeutic efficacy in radiopharmaceutical therapy.